129 related articles for article (PubMed ID: 7606711)
1. Codeletion of p15 and p16 genes in primary non-small cell lung carcinoma.
Xiao S; Li D; Corson JM; Vijg J; Fletcher JA
Cancer Res; 1995 Jul; 55(14):2968-71. PubMed ID: 7606711
[TBL] [Abstract][Full Text] [Related]
2. Codeletion of p15 and p16 in primary malignant mesothelioma.
Xio S; Li D; Vijg J; Sugarbaker DJ; Corson JM; Fletcher JA
Oncogene; 1995 Aug; 11(3):511-5. PubMed ID: 7630635
[TBL] [Abstract][Full Text] [Related]
3. Homozygous deletions at chromosome 9p21 and mutation analysis of p16 and p15 in microdissected primary non-small cell lung cancers.
Packenham JP; Taylor JA; White CM; Anna CH; Barrett JC; Devereux TR
Clin Cancer Res; 1995 Jul; 1(7):687-90. PubMed ID: 9816033
[TBL] [Abstract][Full Text] [Related]
4. Molecular analysis of P16(Ink4)/CDKN2 and P15(INK4B)/MTS2 genes in primary human testicular germ cell tumors.
Heidenreich A; Gaddipati JP; Moul JW; Srivastava S
J Urol; 1998 May; 159(5):1725-30. PubMed ID: 9554401
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of inactivation of CDKN2 and MTS2 in non-small cell lung cancer and association with advanced stage.
Nakagawa K; Conrad NK; Williams JP; Johnson BE; Kelley MJ
Oncogene; 1995 Nov; 11(9):1843-51. PubMed ID: 7478613
[TBL] [Abstract][Full Text] [Related]
6. Hypermethylation of p16(INK4a) and p15(INK4b) genes in non-small cell lung cancer.
Kurakawa E; Shimamoto T; Utsumi K; Hirano T; Kato H; Ohyashiki K
Int J Oncol; 2001 Aug; 19(2):277-81. PubMed ID: 11445839
[TBL] [Abstract][Full Text] [Related]
7. Genetic and epigenetic alterations of the cyclin-dependent kinase inhibitors p15INK4b and p16INK4a in human thyroid carcinoma cell lines and primary thyroid carcinomas.
Elisei R; Shiohara M; Koeffler HP; Fagin JA
Cancer; 1998 Nov; 83(10):2185-93. PubMed ID: 9827724
[TBL] [Abstract][Full Text] [Related]
8. Cell cycle regulators in bladder cancer: relationship to schistosomiasis.
Eissa S; Ahmed MI; Said H; Zaghlool A; El-Ahmady O
IUBMB Life; 2004 Sep; 56(9):557-64. PubMed ID: 15590562
[TBL] [Abstract][Full Text] [Related]
9. A methylthioadenosine phosphorylase (MTAP) fusion transcript identifies a new gene on chromosome 9p21 that is frequently deleted in cancer.
Schmid M; Sen M; Rosenbach MD; Carrera CJ; Friedman H; Carson DA
Oncogene; 2000 Nov; 19(50):5747-54. PubMed ID: 11126361
[TBL] [Abstract][Full Text] [Related]
10. Frequent and selective methylation of p15 and deletion of both p15 and p16 in T-cell acute lymphoblastic leukemia.
Batova A; Diccianni MB; Yu JC; Nobori T; Link MP; Pullen J; Yu AL
Cancer Res; 1997 Mar; 57(5):832-6. PubMed ID: 9041181
[TBL] [Abstract][Full Text] [Related]
11. Aberrant p16 expression is correlated with hemizygous deletions at the 9p21-22 chromosome region in non-small cell lung carcinomas.
Spanakis NE; Gorgoulis V; Mariatos G; Zacharatos P; Kotsinas A; Garinis G; Trigidou R; Karameris A; Tsimara-Papastamatiou H; Kouloukousa M; Manolis EN; Kittas C
Anticancer Res; 1999; 19(3A):1893-9. PubMed ID: 10470133
[TBL] [Abstract][Full Text] [Related]
12. Homozygous deletion of the MTS1/p16 and MTS2/p15 genes and amplification of the CDK4 gene in glioma.
Sonoda Y; Yoshimoto T; Sekiya T
Oncogene; 1995 Nov; 11(10):2145-9. PubMed ID: 7478535
[TBL] [Abstract][Full Text] [Related]
13. In vivo occurrence of p16 (MTS1) and p15 (MTS2) alterations preferentially in non-small cell lung cancers.
Washimi O; Nagatake M; Osada H; Ueda R; Koshikawa T; Seki T; Takahashi T; Takahashi T
Cancer Res; 1995 Feb; 55(3):514-7. PubMed ID: 7834619
[TBL] [Abstract][Full Text] [Related]
14. Genomic structure, expression and mutational analysis of the P15 (MTS2) gene.
Stone S; Dayananth P; Jiang P; Weaver-Feldhaus JM; Tavtigian SV; Cannon-Albright L; Kamb A
Oncogene; 1995 Sep; 11(5):987-91. PubMed ID: 7675459
[TBL] [Abstract][Full Text] [Related]
15. Expression of p15 and p15.5 products in neuroendocrine lung tumours: relationship with p15(INK4b) methylation status.
Chaussade L; Eymin B; Brambilla E; Gazzeri S
Oncogene; 2001 Oct; 20(45):6587-96. PubMed ID: 11641784
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of p16INK4A inactivation in non small-cell lung cancers.
Gazzeri S; Gouyer V; Vour'ch C; Brambilla C; Brambilla E
Oncogene; 1998 Jan; 16(4):497-504. PubMed ID: 9484839
[TBL] [Abstract][Full Text] [Related]
17. Infrequent somatic mutations of the p16 and p15 genes in human bladder cancer: p16 mutations occur only in low-grade and superficial bladder cancers.
Miyamoto H; Kubota Y; Fujinami K; Dobashi Y; Kondo K; Yao M; Shuin T; Hosaka M
Oncol Res; 1995; 7(7-8):327-30. PubMed ID: 8747595
[TBL] [Abstract][Full Text] [Related]
18. Germ-line deletion involving the INK4 locus in familial proneness to melanoma and nervous system tumors.
Bahuau M; Vidaud D; Jenkins RB; Bièche I; Kimmel DW; Assouline B; Smith JS; Alderete B; Cayuela JM; Harpey JP; Caille B; Vidaud M
Cancer Res; 1998 Jun; 58(11):2298-303. PubMed ID: 9622062
[TBL] [Abstract][Full Text] [Related]
19. Frequent loss of heterozygosity on chromosome 9, and low incidence of mutations of cyclin-dependent kinase inhibitors p15 (MTS2) and p16 (MTS1) genes in gliomas.
Li YJ; Hoang-Xuan K; Delattre JY; Poisson M; Thomas G; Hamelin R
Oncogene; 1995 Aug; 11(3):597-600. PubMed ID: 7630644
[TBL] [Abstract][Full Text] [Related]
20. Homozygous codeletion and differential decreased expression of p15INK4b, p16INK4a-alpha and p16INK4a-beta in mouse lung tumor cells.
Herzog CR; Soloff EV; McDoniels AL; Tyson FL; Malkinson AM; Haugen-Strano A; Wiseman RW; Anderson MW; You M
Oncogene; 1996 Nov; 13(9):1885-91. PubMed ID: 8934534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
